בשל "הגנת זכויות יוצרים" מובא להלן קישור לתקציר המאמר. לקריאתו בטקסט מלא, אנא פנה/י לספרייה הרפואית הזמינה לך. 

Intraperitoneal chloroprocaine has been used during cesarean delivery to supplement suboptimal neuraxial anesthesia for decades. The short in vitro half-life of chloroprocaine (11–21 seconds) has been cited to support the safety of this approach.

However, there are no data regarding the rate of absorption, representing patient drug exposure, through this route of administration.

Accordingly, we designed a study to determine the in vivo half-life of intraperitoneal chloroprocaine and assess clinical tolerability.

We designed a single-center, prospective, cohort, multiple-dose escalation study of women 18 to 50 years of age undergoing cesarean delivery with spinal anesthesia.

Chloroprocaine (40 mL) was administered after delivery of the newborn and before uterine closure.

The primary objective was to define the pharmacokinetic profile of intraperitoneal chloroprocaine, including in vivo half-life.

The secondary objective was to evaluate tolerability through determination of peak plasma concentration and prospective assessment for local anesthetic systemic toxicity.